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Background: microRNAs are small noncoding RNAs that modulate a variety of cellular processes by regulating
multiple targets, which can promote or inhibit the development of malignant behaviors. Accumulating evidence
suggests that miR-675-5p plays important roles in human carcinogenesis. However, its precise biological role
remains largely elusive. This study examined the role of miR-675-5p in non- small cell lung cancer (NSCLC).
Methods: The expression of miR-675-5p was analyzed by real-time quantitative PCR (qRT-PCR). The effect of
miR-675-5p on proliferation was evaluated through MTT and colony formation assays, and cell migration and
invasion were evaluated through transwell assays. The expression of target proteins and downstream molecules
was analyzed by western blotting and immunohistochemical staining. The luciferase reporter assay was used to
assess the target genes of miR-675-5p in non-small cell lung cancer cells.
Results: The expression levels of miR-675-5p in NSCLC tissues were significantly reduced compared to those in
adjacent non-cancerous tissues (P < 0.001). The expression of miR-675-5p in patients with non-small cell lung
cancer had a negative correlation with lymph node metastasis (P < 0.01) and TNM stage (P < 0.05). Down-regulation
of miR-675-5p promoted cell growth, proliferation, colony formation, invasion and migration, and promoted the
tumorigenicity graft growth of nude mice in vivo (P < 0.01); whereas up-regulation of miR-675-5p had the contrary
effects. The luciferase reporter assay showed that GPR55 was a direct target gene of miR-675-5p. Overexpression
of miR-675-5p can lead to the down-regulation of GPR55 and its signaling pathway, whereas the effect can be
reversed by down-regulation of miR-675-5p expression.
Conclusions: miR-675-5p functions as a novel tumor suppressor in NSCLC and the anti-oncogenic activity may
involve its inhibition of the target gene GPR55. These findings suggest the possibility for miR-675-5p as a
therapeutic target in NSCLC.
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Lung cancer is a malignant tumor with the highest mor-
bidity and mortality in the world, which is a serious
threat to human health and life security [1]. Non-small
cell lung cancer (NSCLC) accounts for about 80% of all
lung cancer cases, including adenocarcinoma and squa-
mous cell carcinoma [2]. Early lung cancer patients usu-
ally lack obvious symptoms for early diagnosis, and mostly
are late stage lung cancer when diagnosed. In recent years,
although predominantly surgical comprehensive treat-
ment has achieved great progress, the 5-year survival rate
is still less than 15% [3]. Therefore, investigations of the
molecular mechanisms underlying progression and metas-
tasis of NSCLC can help develop novel prognostic bio-
markers and therapeutic targets for the malignancy, and
thus are clinically important. A large number of studies
have shown that abnormal expression of microRNAs
(miRNAs) is closely related to the development of NSCLC
[4-8]. Therefore, as a kind of new molecular target, miR-
NAs have attracted tremendous attention in oncology and
other biomedical research fields.
miRNAs are a class of small noncoding RNAs (19 ~ 24
nucleotide) that regulate the expression of target genes
through binding to the 3′- untranslated region (3′ UTR) of
target genes, resulting in translational repression or mRNA
degradation. miRNA not only can function as a tumor sup-
pressor gene through down-regulation of oncogene activa-
tion, but also as a oncogene through down-regulation of
tumor suppressor gene activation [9,10]. Dysregulation of
miRNAs may lead to many pathological processes that are
very important in the development of cancerous alter-
ations, such as cellular tumorigenesis, differentiation, pro-
liferation, apoptosis, mobility, and invasion [11-14]. Thus,
understanding of the underlying molecular mechanisms of
miRNA dysregulation in malignant tumors is critical to
intervention of lung cancer.
Recent studies have shown that miR-675 expression was
up-regulated in several cancer types, such as glioma [15],
gastric cancer [16,17], colorectal cancer [18] and hepato-
cellular cancer [19]. Another study found low expression
of miR-675 in adrenal cortical carcinoma and metastatic
prostate cancer cells [20,21], implying that miR-675 may
play different roles depending on the tumor type. In this
study, we aimed to evaluate the possible roles and related
target genes of miR-675-5p in tumorigenesis of NSCLC.
We found that the expression level of miR-675-5p was
significantly lower in NSCLC tissues than in the corre-
sponding normal lung tissues, and inversely associated
with advanced stage and lymph node metastasis of
NSCLC. Furthermore, enforced miR-675-5p expression
inhibited lung cancer cell growth, proliferation, clone for-
mation, migration and invasion in vitro, and tumorigen-
icity in vivo. In addition, THE orphan G protein-coupled
receptor 55 (GPR55) was identified as a functional targetof miR-675-5p. Therefore, down-regulation of miR-675-
5p suppresses lung cancer progression and metastasis
through regulation of GPR55.
Results
Expression of miR-675-5p is inversely associated with
advanced stage and lymph node metastasis of NSCLC.
We noticed that miR-675-5p was underexpressed in
NSCLC by using microarray (our unpublished data). To
confirm reduced expression of miR-675-5p in NSCLC,
we evaluated the expression of miR-675-5p in 80 pairs
of frozen NSCLC tissues and the corresponding normal
lung tissues using quantitative reverse transcriptase PCR
(qRT-PCR). The RNA levels of miR-675-5p in NSCLC
tissues were less than 30% of that in the matching normal
tissues (Figure 1A). miR-675-5p expression was signifi-
cantly inversely associated with metastasis and Classifica-
tion of Malignant Tumours (TNM) classification of the
patients (Table 1, P < 0.005). Furthermore, the expression
level of miR-675-5p in tumor tissues decreased statistically
with increasing stage of NSCLC (P < 0.05) (Figure 1B). In
addition, miR-675-5p expression was significantly lower
in NSCLC that displayed lymph node metastasis than in
NSCLC that did not (P = 0.0055). Therefore, the low
miR-675-5p expression was closely related to the pro-
gression and metastasis of NSCLC. We also measured
miR-675-5p expression in six NSCLC cell lines (95-D,
A549, HTB-182, NCI-H1299, SPCA-1, Ltep-a-2) and a
normal human bronchial epithelial cell line (HBE). The
relative expression levels for miR-675-5p in these six
NSCLC cell lines were 0.224, 0.343, 0.378, 0.562, 0.541,
and 0.673, respectively, as compared with that of HBE
cells, respectively (Figure 1D).
Overexpression of miR-675-5p inhibits proliferation,
colony formation, migration, and invasion of NSCLC cells.
As a low level of miR-675-5p expression in NSCLC is
a common molecular incident and is correlated with pro-
gression of the disease, we hypothesize that overexpression
of miR-675-5p in NSCLC can exert inhibitory effects on
cell growth and proliferation. To validate the hypothesis,
we transfected LV-miR-675-precursor or scrambled se-
quence (negative control) into A549 and HTB-182 NSCLC
cells that had low basal levels of miR-675-5p in NSCLC cell
lines (Fig1D). Interestingly, methylthiazol tetrazolium assay
(MTT) showed that forced expression of miR-675-5p im-
paired the growth rate of the NSCLC cells (Figure 2A).
Similarly, colony formation assays showed that cell pro-
liferation in both A549 cells and HTB-182 cells were
significantly repressed by forced expression of miR-675-
5p (Figure 2C). To explore the possible mechanism
underlying the inhibitory effect on cell growth by over-
expression of miR-675-5p, cell cycle analysis was per-
formed (Figure 2B). Upon up-regulation of miR-675-5p,
the percentage of A549 and HTB-182 cells in G0/G1
Figure 1 Down-regulation of miR-675-5p is inversely associated with advanced stage and lymph node metastasis of NSCLC. (A)
miR-675-5p expression level was significantly lower in NSCLC tissues than in their matched normal tissues. (B) Low-level expression of miR-675-5p
was associated with high tumor stage of NSCLC (P < 0.05). (C) Low-level expression of miR-675-5p was related with lymph node metastasis
of NSCLC (P < 0.05). (D) miR-675-5p expression in NSCLC cell lines and normal human bronchial epithelial cell line (HBE). Expression levels of
miR-675-5p were determined by qRT-PCR and normalized against an endogenous control (U6 RNA). Data were represented as the mean ± SEM
of three independent experiments. *P < 0.05, **P < 0.01.
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8.5% and from 52.6% ± 8.0% in controls to 70.0% ± 8.6%,
respectively (P < 0.01), indicating that overexpression of
miR-675-5p resulted in G1 phase arrest in NSCLC cells.
Annexin V fluorescein isothiocyanate (V-FITC) apoptoticTable 1 miR-675-5p expression and clinicopathological
features in non-small cell lung cancer(NSCLC) patients
Variable miR-675-5p expression
Cases Low High P-valuea
Age(years)b
<57 58 43 (74%) 15 (26%) 0.8998
≥57 22 16 (73%) 6 (27%)
Gender
Male 33 24 (73%) 9 (27%) 0.8750
Female 47 35 (74%) 12 (26%)
Smoking history (years)b
<10 36 24 (67%) 12 (33%) 0.2094
≥10 44 35 (80%) 9 (20%)
Pathological type
adenocarcinoma 38 30 (79%) 8 (21%) 0.3391
squamous carcinoma 42 29 (69%) 13 (71%)
Tumor differentiation
I + II 46 37 (80%) 9 (20%) 0.0787
III + IV 34 22 (65%) 12 (35%)
TNM Classification
I 35 19 (54%) 16 (46%) <0.005
II 27 24 (89%) 3 (11%)
III + IV 18 16 (89%) 2 (11%)
Metastasis
No 44 27 (61%) 17 (39%) 0.0055
Yes 36 32 (89%) 4 (11%)
Abbreviations: TNM, tumor-node-metastasis; a×2test. bMean age.assay showed that there was no significant difference of
apoptotic rate between the cells transfected with LV-
miR-675-precursor and control cells (P > 0.05) (data not
shown). Therefore, overexpression of miR-675-5p might
reduce cell proliferation of NSCLC mainly through G1
phase arrest. Furthermore, miR-675-5p overexpression
suppressed the migratory and invasive abilities of the
NSCLC cells as determined by transwell assay (Figure 3A).
Similarly, mobility of A549 and HTB-182 cells in wound
healing assays was significantly decreased after transfec-
tion of miR-675-5p (Figure 3B). Taken together, miR-675-
5p might have tumor-suppressor function.
Overexpression of miR-675-5p inhibits tumor growth
of NSCLC cells in vivo.
Given that miR-675-5p impaired the proliferation, mi-
gration and invasion of NSCLC cells in vitro, we examined
whether miR-675-5p could affect tumorigenicity in vivo.
A549 cells stably expressing miR-675-5p and negative
control vector were injected subcutaneously into nude
mice. Palpable tumors formed within 1 week. Tumor vol-
ume was measured each week, and mice were sacrificed 4
weeks after tumor cell implantation (Figure 4A). The size
of NSCLC tumors in these two groups was calculated and
compared. The average tumor volume of A549 cells stably
transfected with miR-675-5p was 1.23 ± 0.096 cm3, which
was significantly smaller than tumors in the negative
control group (1.86 ± 0.132 cm3) (Figure 4B). The tumor
growth-curve of tumor volume was drawn according to
time and a significant difference was shown between the
two groups (Figure 4C). These results provided further
evidence that miR-675-5p plays a tumor suppressive role
in NSCLC cancer.
GPR55 is a direct downstream target of miR-675-5p.
Next, we searched candidate target genes of miR-675-5p
using publicly available databases. Among the candidates,
GPR55 exhibited one of the highest prediction scores
and the most complementary structure with miR-675-
Figure 2 (See legend on next page.)
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Figure 2 Overexpression of miR-675-5p inhibited proliferation and colony formation of NSCLC cells. (A) the level of miR-675-5p in A549
and HTB-182 cells was significantly up-regulated after transfection with miR-675-precursor. (B) miR-675-5p reduced cell proliferation in NSCLC
cells. Cell proliferation was determined using MTT assays. (C) miR-675-5p induced cell cycle arrest at the G1/S phase. (D) miR-675-5p suppressed
colony formation compared with controls. The number of colonies were calculated and depicted by the ban graph. Data were represented as
the mean ± SEM of three independent experiments. Negative control: pGCsil-GFP Vector. *P < 0.05, **P < 0.01.
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of GPR55 protein was found in various types cancer and
high GPR55 expression is associated with more aggressive
phenotypes [22-26]. Therefore, GPR55 was selected for
further analysis (Figure 5A). To confirm whether GPR55
was a direct target of miR-675-5p, a dual-luciferase re-
porter system was used, employing co-transfection of
miR-675 mimic and a luciferase reporter plasmid contain-
ing the 3′UTR of human GPR55. As shown in Figure 5B,
the intensity of fluorescence after miR-675 mimic co-
transfection was reduced significantly compared with the
negative control; however, no significant variation in lucif-
erase activity was observed for either the GPR55-Mut or
the negative control with miR-675-mimic co-transfection.
Thus, the luciferase assays revealed that miR-675-5p could
bind to the GPR55 3′UTR, causing a significant decrease
in luciferase activity compared with the negative control.
In addition, western blot analysis showed that GPR55
protein expression was clearly decreased in A549 cells
and HTB-182 cells transfected with LV-miR-675-5p-
precursor (Figure 5 C and D). However, the proteinFigure 3 The effect of miR-675-5p on in vitro migration and invasiven
in the miR-675-precursor group was significantly decreased compared with
miR-675-precursor was significantly decreased. Data were represented as th
pGCsil-GFP Vector. *P < 0.05, **P < 0.01.levels of retinoblastoma (RB) protein, a known direct
target of miR-675 in colorectal cancer and another
target prediction of miR-675-5p, IkB kinase TBK1 pro-
tein, was also reported to be necessary in mediating
KRAS-driven tumorigenicity in lung cancer remained
unchanged in A549 cells and HTB-182 cells transfected
with LV-miR-675-5p-precursor (Additional file 2: Figure S1
and Additional file 3: Figure S2) [18,19,27]. These results
indicated that GPR55 was a direct downstream target for
miR-675-5p in NSCLC cells.
Down-regulation of the expression of GPR55 influ-
ences the effects of miR-675 on NSCLC cells
To further ascertain whether GPR55 is a functional
target of miR-675-5p, we transfected with LV-miR-675-
5p inhibitor into Ltep-a-2 NSCLC cells, which have high
endogenous miR-675-5p levels (Figure 1D). Compared
with control cell group (scrambled sequence), the cells
transfected with miR-675-5p inhibitor displayed higher
expression of GPR55, whereas the cells with the co-
transfection of both LV-miR-675-5p inhibitor and si-
GPR55 exhibited lower GPR55 expression (Figure 6A).ess of NSCLC cells. (A) The number of migrating or invading cells
the control. (B) The wound healing rate in cells transfected with
e mean ± SEM of three independent experiments. Negative control:
Figure 4 Overexpression of miR-675-5p inhibits NSCLC in vivo. (A) Tumor volumes of subcutaneous implantation models of NSCLC are
shown. (B) Tumor growth curves of subcutaneous implantation models of NSCLC. (C) Tumor volumes in the orthotopic implantation models at
week 4 are shown. Data were represented as the mean ± SEM of three independent experiments. Negative control: pGCsil-GFP Vector *P < 0.05.
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inhibitor displayed higher proliferation, migration and
invasion potential when compared with the cells trans-
fected with both LV-miR-675-5p inhibitor and si-GPR55
(Figure 6B-F). We also transfected with si-GPR55 into
A549 NSCLC cells, which have high endogenous GPR55
levels (new Additional file 4: Figure S3) and lower en-
dogenous miR-675-5p levels (Figure 1D), and the expres-
sion of GPR55 in the cells determined by Western
blotting. Compared with control cell group (non-specific
control siRNA, si-NC), the cells transfected with si-
GPR55 displayed lower expression of GPR55 and the
cells transfected with si-GPR55 displayed lower growth
rate compared with the cells transfected with si-NC.
(Additional file 4: Figure S3). These observations sug-
gest that the effects of miR-675-5p down-regulation on
the promotion of cancer cell proliferation, migration and
invasion could be diminished by si-GPR55. Therefore,Figure 5 GPR55 is a direct downstream target of miR-675-5p. (A) Sche
vectors is illustrated. (B) Relative luciferase activity was analyzed in A549 ce
Related expression of GPR55 protein in A549 and HTB-182 cells treated wit
were represented as the mean ± SEM of three independent experiments. NGPR55 may mediate cell proliferation, migration and inva-
sion of NSCLC induced by miR-675-5p.
MiR-675-5p inhibits the GPR55 signaling pathway.
To explore whether miR-675-5p exerts its functions
through the GPR55-ERK and/or GPR55-RhoA pathways
that contribute to cancer proliferation, development and
progression [28-31], we examined a number of the main
GPR55 signaling downstream target genes, including
phosphorylation of extracellular signal regulated kinase
(p-ERK), ERK, Cyclin D1 protein (cyclin D1), active
form of RhoA (GTP-RhoA), matrix metalloproteinase-2
(MMP2), and MMP9. Expression of p-ERK, cyclin D1,
GTP-RhoA, MMP2 and MMP9 were decreased in A549
and HTB-182 cells that stably overexpressed miR-675-5p
(Figure 7, left and middle, lane 3). In contrast, expression
of these genes was significantly up-regulated in Ltep-a-2
cells with stable down-regulation of miR-675-5p (Figure 7,
right, lane 2) compared with negative control cell groupmatic of the construction of wild-type or mutant pGL3-GPR55 3′-UTR
lls. Firefly luciferase vector was used as an internal control. (C and D)
h miR-675 precursor was determined by western blot analysis. Data
egative control: pGCsil-GFP Vector. *P < 0.05, **P < 0.01.
Figure 6 Requirement of GPR55 for miR-675-5p induced suppression of NSCLC cell proliferation, migration and invasion. (A) the level
of miR-675-5p in the cells was significantly down-regulated after transfection with miR-675-5p inhibitor. (B) GPR55 was knockdowned in Ltep-a-2
miR-675-5p inhibition cells and analyzed by western blot analysis. Knockdown of GPR55 significantly inhibited proliferation (C), inhibited colony
formation (D), induced cell cycle arrest at the G1/S phase (E), inhibited migration and invasion (F), and decreased the wound healing rate (G) in
Ltep-a-2 cells. Data were represented as the mean ± SEM of three independent experiments. Negative control: pGC FU-RNAi-NC-LV.
*P < 0.05, P* < 0.01.
Figure 7 miR-675-5p-mediated inhibition of the GPR55 signaling pathway. In A549 and HTB-182 cells with miR-675-5p overexpression, the
protein levels of p-ERK, Cyclin D, GTP-RhoA, MMP9 and MMP2 (left and middle, lane 3) were significantly decreased compared with the control.
In Ltep-a-2 cells with miR-675-5p down-regulated expression, the protein levels of p-ERK, Cyclin D, GTP-RhoA, MMP9 and MMP2 (right, lane 2)
were significantly increased compared with the negative control(right, lane 1) and si-GPR55 treatment abrogated the increased expression of
these genes induced by miR-675-5p in the cells (right, lane 4). However, the expression of these genes has not changed in Ltep-a-2 cells (stable
down-regulation of miR-675-5p) transfected with non-specific control siRNA (si-NC) (Figure 7, right, lane 3). Knockdown of GPR55 inhibited the
expression of GPR55 and its main target genes, similar to miR-675-5p (right).
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knockdown of the expression of GPR55 using GPR55-
specific siRNA (si-GPR55) (Fig6A, lane 4) abrogated the
effects induced by miR-675-5p down-regulation (Figure 7,
right, lane 4). However, the expression of these genes did
not change in Ltep-a-2 cells (stable down-regulation of
miR-675-5p) transfected with non-specific control siRNA
(si-NC) (Figure 7, right, lane 3). These data indicate that
miR-675-5p inhibits GPR55 signaling in NSCLC, which
involved tumor development and progression.
Up-regulation of GPR55 is inversely associated with
down-regulation of miR-675-5p in clinical specimens of
NSCLC.
To further investigate the clinical significance of GPR55
expression, we examined GPR55 expression using immu-
nohistochemical analysis on FFPEs of 80 NSCLC speci-
mens. As shown in Figure 8A, GPR55 antibody exhibited
negative or weak staining in alveolar epithelial cells of nor-
mal lung tissue. In contrast, GRP55 antibody displayed
positive staining in tumor tissues with different intensity
(Figure 8B and C). Furthermore, GRP55 expression was
positively correlated with tumor, nodes and metastasis-
classification (TNM) stage (P < 0.02) and lymph node me-
tastasis of NSCLC (P < 0.01) (Additional file 5: Table S1).Figure 8 Inverse correlation between the expression of GPR55 and m
of GPR55 was assessed in normal and NSCLC tissues using immunohistoch
squamous carcinoma, and adenocarcinoma, respectively. (D) A scatter diag
miR-675-5p and GPR55 in the same set of NSCLC tissue specimens. (originaTaken together, GPR55 was frequently overexpressed in
NSCLC and the elevated expression was positively associ-
ated with the progression of the disease.
To explore the relationship between miR-675-5p and
GPR55 in clinical specimens, we compared GPR55 ex-
pression data from immunohistochemistry analysis with
results of miR-675-5p expression level from qRT–PCR
analysis on specimens of these NSCLC tissues. There was
an inverse correlation between miR-675-5p and GPR55
expressions in these specimens (Figure 8D, R = -0.825,
P < 0.001).
Discussion
The abnormal expression of miRNAs has been reported
in many types of cancer, and considerable attention is
focused on understanding the role of miRNAs in the
process of cancer development [32,33]. In the present
study, we first found that miR-675-5p was frequently
down-regulated in lung tumor tissues and the reduced
miR-675-5p expression was closely related to advanced
stage and lymph node metastasis of NSCLC. Further-
more, we demonstrated that miR-675-5p overexpression
could suppress NSCLC cell proliferation, migration and
invasion in vitro and tumor growth in vivo. In addition,iR-675-5p in clinical specimens of NSCLC. (A, B, C) The expression
emistry. The images were representative IHC of GPR55 in normal,
ram showed an inverse correlation between the expression of
l magnification ×400).
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of miR-675-5p. Therefore, miR-675-5p could be a novel
tumor-suppressor miRNA, and its down-regulation might
contribute to lung cancer progression and metastasis
through regulating GPR55 function. The versatile func-
tions of miR-675-5p in tumor cell proliferation, migration
and invasion suggest its potential application as a prog-
nostic predictor and cancer therapeutic target.
We have provided the following lines of evidence
that miR-675-5p inhibits tumor growth, proliferation and
migration in part by suppressing GPR55. (A) The mRNA
levels of miR-675-5p were inversely correlated with GPR55
levels in NSCLC tissues. (B) Up-regulation of miR-675-5p
significantly reduced GPR55 levels in NSCLC cells, whereas
inhibition of miR-675-5p increased GPR55 levels. (C) Over-
expression of miR-675-5p decreased the luciferase reporter
activity of wild-type 3′- UTR but not mutant 3′-UTR of
GPR55. (D) More importantly, the effects of miR-675-5p
antagonists on cell proliferation, migration and invasion of
NSCLC cells were abrogated by silencing of the GPR55
gene. These data support GPR55 as a downstream medi-
ator of miR-675-5p function in NSCLC.
GPR55 is a G protein-coupled receptor with lipid-
sensing properties and its up-regulation contributes to
the aggressive behavior of various cancer types [22-26].
Andradas et al. found that most human cancer cell lines
express detectable levels of GPR55 mRNA [28]. Higher
GPR55 expression is associated with more aggressive
phenotypes (higher histological grades and higher prolif-
erative rates) in human breast tumors [28], pancreatic
tumors [26] and glioblastomas [34]. Overexpression of
GPR55 enhanced cell proliferation via extracellular signal-
regulated protein kinase [28]. Ford et al found that the
highly metastatic MDAMB-231 cell line expressed higher
levels of GPR55 than the non-metastatic MCF-7 cell line
and overexpression of GPR55 in MCF-7 cells enhanced
their migration [30]. This suggests that signals from
GPR55 could control not only cell proliferation but also
cell migration and invasion. GPR55 activation resulted
in increasing migration and invasion is likely through
activation of RhoA that regulates cell morphology and
mobility as well as membrane trafficking [31]. In the
present study, we examined the expression of GPR55
signaling downstream target genes and found that ex-
pression of p-ERK, cyclin D1, MMP2 and MMP9 were
decreased in NSCLC cells that stably overexpressed miR-
675-5p. In contrast, expression of these genes was signifi-
cantly up-regulated in NSCLC cells that stably expressed
miR-675-5p inhibitor. Moreover, knockdown expression
of GPR55 abrogated the effects induced by miR-675-5p
-inhibitor. Cyclin D1 is a crucial mediator of G1 to S pro-
gression [35]. Up-regulation of cyclin Dl results in rapid
growth of a subset of NSCLC [35]. Thus, down-regulation
of cyclin D1 through inhibition of GPR55 could be amechanism by which miR-675-5p suppresses cell prolifer-
ation and promotes cell cycle arrest at the G1 phase.
MMPs are a family of enzymes that proteolytically degrade
various components of the extracellular matrix [36]. High
levels of certain MMPs are closely correlated with the
invasive and metastatic potential of tumors [37,38]. Specif-
ically, activated RhoA regulates tumor invasion of lung
cancer cells by regulating gene transcription of MMP2
and MMP9 [39,40]. In contrast, blocking RhoA activity
significantly inhibits MMP2 and MMP9 expression, tumor
invasion, and lung metastasis [40,41]. Therefore, down-
regulation of the RhoA-MMP2/9 axis through inhibition
of GPR55 is one of the important mechanisms underlying
miR-675-5p-mediated inhibition of NSCLC invasion and
metastasis. These data indicate that miR-675-5p sup-
presses progression of NSCLC through inhibition of the
versatile tumor-promoting GPR55. It is noteworthy that
neither miR-675 nor GPR55 has been investigated in
NSCLC. Our report revealed a novel miR-675-GPR55
axis in regulation of NSCLC.
GPR55 is identified as a target of miR-675-5p. How-
ever, the antioncogenic properties of miR-675-5p might
not solely be explained by its ability to regulate a single
gene alone, because a single miRNA can potentially regu-
late dozens to hundreds of genes in tumorigenesis [42].
Indeed, we identified at least 12 other potential targets of
miR-675-5p using bioinformatic prediction analysis, in-
cluding some tumor-related genes. For instance, TGFBI
was recently proposed as a biologically relevant miR-675-
5p target in prostate cancer [20]. TGFBI is an extracellular
protein that promotes epithelial-mesenchymal transition
and cancer metastasis [43]. Up-regulation of miR-675 in
the prostate cancer cell line significantly decreased the
level of TGFBI and repressed cell migration. Therefore,
we cannot exclude the possibility that these candidate tar-
gets for miR-675-5p besides GPR55 could mediate tumor-
suppressive function of miR-675-5p. We are exploring the
correlation between miR-675-5p and other target candi-
dates and determining whether miR-675-5p can biologic-
ally regulate the potential targets in a different study.
Another example is pRB, a tumor suppressor that is tar-
geted by miR-675 in colorectal cancer in which miR-675
acts as an oncogene [18,19] and IkB kinase TBK1 [27]. In-
triguingly we did not observe any significant alteration at
the protein levels of pRB and TBK1 by miR-675-5p in
NSCLC cells (Additional file 2: Figure S1 and Additional
file 3: Figure S2). These findings suggest miR-675 regu-
lates its target genes and cancer cell behaviors in a cell or
tissue type-specific in cancer. On the other hand, bioinfor-
matic analysis suggests that the GPR55 may be targeted
by more than 10 different miRNAs, implying that other
miRNAs may also regulate function of GPR55 in lung
tumorigenesis. For example, miR-3187-5p is one of the
miRNAs that are predicted as candidates to regulate
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patients with bladder cancer and low miR-31 87-3p level
is associated with tumor invasion [44]. Therefore, future
studies to identify additional novel targets of miR-675-
5p and other miRNAs that can also regulate GPR55 will
allow us to have deep understanding of the mechanisms
underlying the development and progression of NSCLC.
H19 has been shown to be the primary miRNA pre-
cursor of miR-675 in both human and mice and also
been identified as a developmental reservoir of miR-675
that suppresses growth [45,46]. We evaluated the ex-
pression of miR-675-5p in NSCLC tissues and the corre-
sponding normal lung tissues using quantitative reverse
transcriptase PCR. There is no difference between the
RNA levels of H19 in NSCLC tissues and that in the
matching normal tissues (new Additional file 6: Figure S4).
Because H19 is unchanged, we speculate down-regulation
of miR-675-5p in NSCLC results from post-transcriptional
regulation instead of transcriptional repression of miR-
675-5p’s primary transcript H19. Downregulation of
miR-675-5p may result from reduced conversion of H19
into pre-miR-675 and/or reduced conversion of pre-
miR-675 into mature miR-675-5p.
Conclusions
Carcinogenesis is a series of sequential events, including
growth, proliferation, migration, and local invasion. Herein,
we showed that miR-675-5p could suppress the carcino-
genesis of NSCLC through inhibition of growth, prolifera-
tion, migration and invasion. Furthermore, our evidence
suggests that miR-675-5p is a potential therapeutic target
in NSCLC. Further studies are required to fully understand
the detailed mechanisms of miR-675-5p in NSCLC car-
cinogenesis and as a potential therapeutic approach.
Materials and Methods
Ethical statement
Written informed consent was obtained from all partici-
pants, and the study protocol was approved by the ethics
committee of Xiangya Hospital, Central South University
(CSU). All mouse experiments were approved by the
Animal Care and Use Committee (Permit#201403238)
and conducted in accordance with the official recom-
mendations of the Care and Use Laboratory Animals of
Xiangya Hospital, CSU.
Patient and tissue samples
Primary cancer tissues and paired adjacent non-tumor
tissues were collected from 80 patients with NSCLC
underwent lung resection at the Department of Surgery,
Xiangya Hospital of Central South University from May
2011 to December 2013. Patients did not receive any
preoperative cancer treatments, such as radiotherapy or
chemotherapy. Each specimen was rapidly frozen in liquidnitrogen, and transferred to the -80°C refrigerator for sub-
sequent experiments. The collected samples were con-
firmed by an experienced pathologist. The clinical data of
NSCLC patients including tumor-node metastasis (TNM)
staging were also collected.Cell lines and cell culture
Six NSCLC cell lines (HTB-182, A549, SPC-A-1, H1299,
95-D, Ltep-a-2) were obtained from the American Type
Culture Collection. A normal human bronchial epithelial
cell line (HBE), were purchased from the Institute of
Biochemistry and Cell Biology of the Chinese Academy
of Sciences (Shanghai, China). Cells were cultured in
RPMI 1640 (GIBCO-BRL) medium supplemented with
10% fetal bovine serum (10% FBS), 100 U/ml penicillin,
and 100 μg/ml streptomycin (Biyuntian, China) in humidi-
fied air at 37°C with 5% CO2.RNA extraction and qRT-PCR analyses
Total RNA was extracted from cell lines and frozen tumor
specimens using Trizol reagent (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s protocol. qRT-PCR
assays were performed to detect miR-675-5p and GPR55
expression using the PrimeScript RT reagent Kit and
SYBR Premix Ex Taq (GeneCopoeia, USA) according to
the manufacturer’s instructions. The relative level of
miR-675-5p and GPR55 was determined by qRT-PCR
using gene specific primers. U6 or β-actin was used as a
normalization control. Levels of miR-675-5p and GPR55
were normalized to U6 and β-actin, respectively, to yield a
2-ΔΔCt value for relative expression of each transcript. Ex-
periments were repeated at least three times.
The RT reaction was carried out under the following
conditions: 37°C for 60 min; 85°C for 5 min; and then
held on 4°C. After the RT reaction, the complementary
DNA products were diluted at1:10 and 2 μl of the diluted
complementary DNA was used for subsequent qRT-PCR









reaction was conducted at 95°C for 10 s and followed by
40 cycles of 95°C for 10 s, 60°C for 20 s and 72°C for
10 s in the ABI 7500 real-time PCR system (Applied
Biosystems, CA, USA). The qRT-PCR results were ana-
lyzed and expressed as relative miRNA expression of
CT (threshold cycle) value, which was then converted to
fold changes.
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The hsa-miR-675-precursor sequence was constructed
as follows: (Forward) hsa-miR-675-Age I-F ACCGGTG
GAGGGCGAAGC, (Reverse) hsa-miR-675-EcoR I-R GA
ATTCAAAAACTCCTGAGAG. The sequence was ampli-
fied and cloned into the pGCsil-GFP Vector (GeneChem
Co., Shanghai, China) to generate pGCsil-GFP-miR-675
and the pGCsil-GFP Vector only as negative control. The
hsa-miR-675-5p-inhibition sequence was constructed as
follows: (Forward) hsa-miR-675-5p-inhibition-Age I-F
AATTCAAAAATGGTGCGGAGAGGGCCCACAGTG,
(Reverse) hsa-miR-675-5p-inhibition-EcoR I-R CCGG
CACTGTGGGCCCTCTCCGCACCATTTTTG. The se-
quence was amplified and cloned into the pGCsil-GFP
Vector to generate pGCsil-GFP-miR-675-5p-inhibition.
The non-silencing shRNA control sequences(TTCTCCG
AACGTGTCACGT) was cloned into the pGCsil-GFP
Vector as negative control (pGC FU-RNAi-NC-LV). Virus
packaging, production and cell transfection were per-
formed according to the manufacture’s protocol. The
expression was validated by qRT-PCR. GPR55-siRNA
(si-GPR55) and non-specific control siRNA (si-NC) were
purchased from GeneChem, Shanghai, China.
Cell proliferation, cell cycle and colony formation assays
Cell proliferation was monitored using Cell Proliferation
Reagent Kit I (MTT) (Sigma). LV-miR-675-precursor,
LV-negative control transfected A549 and HTB-182 or
miR-675-5p-inhibition, or pGC FU-RNAi-NC-LV (Nega-
tive control) transfected Ltep-a-2 cells (3000/well) were
allowed to grow in 96-well plates. Cell proliferation was
documented every 24 h following the manufacturer’s
protocol. Cell cycle analyses were performed using pro-
pidium iodide (Keygen, Nanjing, China). For cell cycle
analysis, cells were seeded in 6-well plates at 2 × 105 per
well. Forty-eight hours after transfection, cells were fixed
in 70% ethanol at 4°C for 24 hours and stained with 50
μg/mL propidium iodide (Keygen, Nanjing, China). The
cell cycle distribution was analyzed by flow cytometry
(Epics Altra, Beckman Coulter,USA). For the colony for-
mation assay, LV-miR-675-5p-inhibition, LV-negative
control transfected A549 and HTB-182 cells or miR-675-
5p-inhibition, pGC FU-RNAi-NC-LV (Negative control)
transfected Ltep-a-2 cells (1000/well) were allowed to
grow in culture dish(10-cm) and maintained in media
containing 10% FBS, replacing the medium every 4 days.
After 10 days, cells were fixed with methanol and stained
with 0.1% crystal violet (Biyuntian, Beijing, China). Visible
colonies were manually counted. All experiments were
performed in triplicate.
In vitro cell migration and invasion assays
For the migration assays, 48 h after transfection, 2 × 104
cells in serum-free media were placed into the upperchamber of an insert (8-μm pore size, BD). For the inva-
sion assays, 1 × 105 cells in serum-free media were
placed into the upper chamber of an insert coated with
Matrigel (BD, USA). Media containing 10% FBS were
added to the lower chamber. After 48 hours of incubation,
removing the cells remaining on the upper membrane
with cotton wool, whereas the cells that had migrated or
invaded through the membrane were stained with 0.1%
crystal violet in methanol, imaged, and counted using an
inverted microscope (Canon, Japan). For wound-healing
assay, cells (1 × 106 cells) were seeded in six-well plates,
cultured overnight and transfected with miR-675-
precursor, negative control or miR-675-5p-inhibition,
pGC FU-RNAi-NC-LV (Negative control). Upon reaching
the appropriate confluence, the cell layer was scratched
with a sterile plastic tip and washed with culture medium
twice and cultured again for up to 72 h with serum-free
medium. Images were captured at different time points (0,
36 and 72 h) under a microscope to assess the rate of gap
closure. Every experiment was repeated three times.
Bioinformatics methods
Using bioinformatics software (DIANA TOOL, Targetscan,
miRanda) to predict miR-675-5p potential target gene,
combined with the literature and through the test screen-
ing, GPR55 was selected as a further object of study.
Luciferase reporter assay
To construct a luciferase reporter vector, GPR55 3′-UTR
fragment containing putative binding sites for miR-675-5p
was amplified by PCR using the following primers: h-
GPR55-F: CCGACTCGAGCGGAAGGACATCCTGTTC
AG h-GPR55-R: ATTGCGGCCGCCTTTCCAGAACCT
CCCAGTC, the PCR product was subcloned downstream
of the luciferase gene in the pLUC Luciferase vector
(Ruibo, Guangzhou,China) and named GPR55-3′-UTR-
WT. For the mutated construct, using the following
primers: h-GPR55-mut-F: GGATGATGGCGTGGTTCT
TCACTGATGTGCTTC. h-GPR55 -mut-R: GTGAAGA
ACCACGCCATCATCCCACCACATCA.
A549 cells grown in 96-well plate were co-transfected
with 50 nM miR-675 mimic or mimic negative control,
100 ng of GPR55-3′UTR-Wt or GPR55-3′UTR-Mut, using
the Lipofectamie 2000 (Invitrogen, USA). After 48 h of
transfection, luciferase activity was assessed according to
the Dual-Luciferase Reporter Assay protocol (Promega,
Madison, WI). Each experiment was repeated in triplicates.
Western blotting and RhoA activation assay
Total protein was extracted by lysing cells in RIPA buffer
containing protease inhibitor. Protein samples were sep-
arated by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto poly-
vinylidene fluoride (PVDF) membranes. After blocking
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were incubated with the primary antibody. The follow-
ing antibodies were used: GPR55 (1:1000, Cayman,
USA), ERK1 (1:2000, Santa Cruz, USA), p-ERK1/2 (1:2000,
SantaCruz,USA), anti-cyclinD1 (1:2000), MMP2 (1:1000,
Proteintech.,USA), MMP9 (1:1000, Proteintech Group,
USA), RB(1:1000, Proteintech Group,USA), Tubulin
(1:3000, Abcam, USA) and β-actin (1:3000, Bioword,
Britain) TBK1(1:2000, Upstate Biotechnologies/Millipore,
Billerica, MA) and goat-anti-rabbit IgG conjugated to
horseradish peroxidase (HRP) (1:5000, Santa Cruz, USA),
which was used as the secondary antibody. Cells were
seeded on 10-cm cell culture plates, grown to 80% con-
fluency, and serum starved overnight. To evaluate the ac-
tivity of RhoA, the cells washed twice with ice-cold TBS
and harvested on ice with 500 μl of 1X MLB lysis buffer
(Upstate Biotechnology Inc.). Lysates were then clarified
by centrifugation at 14,000 g for 10 min. The cell lysates
were incubated with 30 μg of GST-RBD-agarose beads to
precipitate GTP-bound RhoA. The beads were pelleted by
brief centrifugation (12,000 g for 30 s), and washed 3
times with lysis buffer. Samples were denatured in sample
buffer, boiled for 5 min at 90°C, and resolved using a 12%
SDS-PAGE gel. Bound RhoA was detected by Western
blot using a monoclonal anti-RhoA antibody, followed
by secondary antibody incubation. Bands were visual-
ized using the enhanced chemiluminescence kit (Santa
Cruz Biotechnology, Santa Cruz, CA). Target signals
were quantified by BandScan software (Bio-Rad, Hercules,
CA) and defined as the ratio of target protein relative to
β-actin or β-tubulin.
NSCLC mouse model
Five-week-old BALB/C-nu nude male mice were used
for animal studies, and all animals were maintained in
the specific pathogen-free (SPF) conditions at our insti-
tution. For the in vivo tumor proliferation assay, 2 × 106
A549 cells transfected with LV-miR-675-precursor or
LV-negative control were injected subcutaneously into
the nude mice (6 per group). Tumor growth was moni-
tored by caliper measurement once or twice a week for
at least 4 weeks. Tumor volume was calculated as fol-
lows: V = L × l2 × 0.5, where L and l represent the larger
and the smaller tumor diameters, respectively. The mice
were sacrificed after 4 weeks.
Immunohistochemical staining
Formalin-fixed, paraffin-embedded tissues were cut into
4-μm sections. Following deparaffinization, sections were
rehydrated and subjected to antigen retrieval by micro-
waving in 0.01 M sodium citrate (pH 6) for 10 minutes.
Sections were incubated at 4°C overnight with monoclonal
antibodies against GPR55 as mentioned above. Immuno-
staining was performed using ChemMate DAKO EnVisionDetection Kit, Peroxidase/DAB, Rabbit/Mouse (code K
5007, DakoCytomation, Glostrup, Denmark) according
to the manufacturer’s instructions. Subsequently, sec-
tions were counterstained with hematoxylin (Dako) and
mounted in dimethyl benzene. Protein staining was
evaluated under a light microscope at 400× magnifica-
tion. Staining intensity was scored manually by two in-
dependent experienced pathologists as 0 = no staining,
1 = weak staining, 2 = moderate staining, and 3 = strong
staining. Tumor cells in five fields were randomly se-
lected and scored based on the percentage of positively
stained cells (0-100%). The final IHC score was calcu-
lated by multiplying the intensity score with the per-
centage of positive cells.
Statistical analysis
The relationship between miR-675-5p expression and clin-
icopathologic parameters was analyzed using the Pearson
X2 test. Spearman’s correlation analysis was used to deter-
mine correlation between miR-675-5p and GPR55 expres-
sion. The differences between groups were analyzed using
Student t test when there were only two groups, or
assessed by one-way ANOVA when there were more than
two groups. All statistical analyses were performed using
the SPSS software (version 16.0, Chicago, IL). A two-tailed
value of P < 0.05 was considered statistically significant.
Additional files
Additional file 1: Table S2. The target prediction of miR-675-5p from
websites DIANA TOOL Targetscan and miRanda,the GRP55 score is 0.916
(from DIANA TOOL, miTG score), -0.64(from Targetscan),-0.4313 and
-0.1271(from miRanda, mirSVR score )and other target genes prediction
of miR-675-5p score has been included in Additional file 1: Table S2 or
refer to DIANA TOOL, Targetscan and miRanda websites. Additional file 1:
Table S2 79 targets prediction of miR-675-5p from websites DIANA TOOL.
Threshold is set to 0.7.
Additional file 2: Figure S1. The expression of retinoblastoma (RB)
protein which a known direct target of miR-675 has not changed in
A549 cells and HTB-182 cells transfected with LV-miR-675-5p-precursor.
The expression of RB in the cells determined by Western blotting. RB
expression was normalized using β-tubulin expression.
Additional file 3: Figure S2. The expression of the non-canonical IkB
kinase TBK1 protein which a target prediction of miR-675 has not
changed in A549 cells and HTB-182 cells transfected with LV-miR-675-5p-
precursor. The expression of TBK1 in the cells determined by Western
blotting. TBK1 expression was normalized using β-tubulin expression.
Additional file 4: Figure S3. Down-regulation of the expression of
GPR55 inhibits the growth of on the A549 NSCLC cells. The expression
of GPR55 protein in the A549 cells transfected with si-GPR55 determined
by Western blotting. Compared with control cell group(non-specific
control siRNA, si-NC), the cells transfected with si-GPR55 displayed
lower expression of GPR55(left) and the cells transfected with si-GPR55
displayed lower growth rate compared with the cells transfected with
si-NC(right).
Additional file 5: Table S1. Correlations between GPR55 expression
and clinicopathological variables in patients with NSCLC.
Additional file 6: Figure S4. The expression of H19 in NSCLC tissues
and the matching normal tissues were determined by qRT-PCR and
He et al. Molecular Cancer  (2015) 14:73 Page 13 of 14normalized against an endogenous control (U6 RNA). There is no
difference between the RNA levels of H19 in NSCLC tissues and that in
the matching normal tissues. Data were represented as the mean±SEM
of three independent experiments.
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